Propanc Biopharma, Inc. (PPCB)
USD 5.5
(-25.98%)
USD 5.5
(-25.98%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 72.36 Thousand USD | 19.95% |
| 2023 | 60.32 Thousand USD | -26.11% |
| 2022 | 81.65 Thousand USD | 523.24% |
| 2021 | 13.1 Thousand USD | -86.7% |
| 2020 | 98.51 Thousand USD | -3.08% |
| 2019 | 101.65 Thousand USD | 42.4% |
| 2018 | 71.38 Thousand USD | -24.91% |
| 2017 | 95.06 Thousand USD | -74.93% |
| 2016 | 379.14 Thousand USD | -39.54% |
| 2015 | 627.06 Thousand USD | 451.29% |
| 2014 | 113.74 Thousand USD | 6410.88% |
| 2013 | 1747.00 USD | -96.22% |
| 2012 | 46.26 Thousand USD | -99.57% |
| 2011 | 10.81 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 180.37 Thousand USD | 198.98% |
| 2024 Q3 | 37.33 Thousand USD | -84.57% |
| 2024 Q4 | 72.36 Thousand USD | 93.82% |
| 2024 Q2 | 241.9 Thousand USD | 34.12% |
| 2023 Q3 | 143.74 Thousand USD | 33.07% |
| 2023 Q1 | 94.25 Thousand USD | 15.44% |
| 2023 FY | 60.32 Thousand USD | -26.11% |
| 2023 Q2 | 108.02 Thousand USD | 14.61% |
| 2023 Q4 | 60.32 Thousand USD | -58.03% |
| 2022 Q1 | 62.16 Thousand USD | 374.51% |
| 2022 FY | 81.65 Thousand USD | 523.24% |
| 2022 Q4 | 81.65 Thousand USD | -51.82% |
| 2022 Q3 | 169.46 Thousand USD | 53.81% |
| 2022 Q2 | 110.17 Thousand USD | 77.23% |
| 2021 Q2 | 40.61 Thousand USD | -47.63% |
| 2021 Q1 | 77.55 Thousand USD | -21.28% |
| 2021 FY | 13.1 Thousand USD | -86.7% |
| 2021 Q4 | 13.1 Thousand USD | -53.28% |
| 2021 Q3 | 28.04 Thousand USD | -30.96% |
| 2020 Q1 | 197.66 Thousand USD | 94.45% |
| 2020 Q2 | 65.42 Thousand USD | -66.9% |
| 2020 Q3 | 63.93 Thousand USD | -2.27% |
| 2020 FY | 98.51 Thousand USD | -3.08% |
| 2020 Q4 | 98.51 Thousand USD | 54.08% |
| 2019 FY | 101.65 Thousand USD | 42.4% |
| 2019 Q3 | 259.91 Thousand USD | -63.53% |
| 2019 Q2 | 712.59 Thousand USD | 760.88% |
| 2019 Q1 | 82.77 Thousand USD | 15.95% |
| 2019 Q4 | 101.65 Thousand USD | -60.89% |
| 2018 FY | 71.38 Thousand USD | -24.91% |
| 2018 Q3 | 110.74 Thousand USD | -14.2% |
| 2018 Q2 | 129.08 Thousand USD | -20.57% |
| 2018 Q1 | 162.51 Thousand USD | 70.94% |
| 2018 Q4 | 71.38 Thousand USD | -35.54% |
| 2017 Q1 | 181.39 Thousand USD | -52.16% |
| 2017 Q2 | 135.83 Thousand USD | -25.11% |
| 2017 Q3 | 44.78 Thousand USD | -67.03% |
| 2017 Q4 | 95.06 Thousand USD | 112.27% |
| 2017 FY | 95.06 Thousand USD | -74.93% |
| 2016 Q1 | 305.12 Thousand USD | -51.34% |
| 2016 FY | 379.14 Thousand USD | -39.54% |
| 2016 Q4 | 379.14 Thousand USD | -76.64% |
| 2016 Q3 | 1.62 Million USD | 7.63% |
| 2016 Q2 | 1.5 Million USD | 394.23% |
| 2015 Q1 | 51.57 Thousand USD | -54.66% |
| 2015 FY | 627.06 Thousand USD | 451.29% |
| 2015 Q2 | 52.94 Thousand USD | 2.65% |
| 2015 Q4 | 627.06 Thousand USD | 102.53% |
| 2015 Q3 | 309.62 Thousand USD | 484.86% |
| 2014 Q1 | 38.71 Thousand USD | 2116.2% |
| 2014 FY | 113.74 Thousand USD | 6410.88% |
| 2014 Q4 | 113.74 Thousand USD | 284262.5% |
| 2014 Q3 | 40.00 USD | -99.66% |
| 2014 Q2 | 11.92 Thousand USD | -69.2% |
| 2013 Q4 | 1747.00 USD | -57.78% |
| 2013 FY | 1747.00 USD | -96.22% |
| 2013 Q3 | 4138.00 USD | -66.36% |
| 2013 Q2 | 12.3 Thousand USD | -54.59% |
| 2013 Q1 | 27.08 Thousand USD | -41.46% |
| 2012 Q3 | 2.15 Million USD | -55.7% |
| 2012 Q4 | 46.26 Thousand USD | -97.86% |
| 2012 FY | 46.26 Thousand USD | -99.57% |
| 2012 Q2 | 4.87 Million USD | 0.0% |
| 2011 Q4 | 10.81 Million USD | 0.0% |
| 2011 FY | 10.81 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -3032.684% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 96.304% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.314% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 86.893% |
| Rebus Holdings, Inc. | 5000.00 USD | -1347.3% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.944% |
| Qrons Inc. | 420.00 USD | -17129.762% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 90.61% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.741% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 84.941% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.394% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.814% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.998% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 5.224% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.932% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 94.947% |
| Mesoblast Limited | 667.9 Million USD | 99.989% |
| Marizyme, Inc. | 22.01 Million USD | 99.671% |
| Genus plc | 1.02 Billion USD | 99.993% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 94.673% |
| Pharming Group N.V. | 462.85 Million USD | 99.984% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 97.816% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 85.499% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 88.459% |
| ContraFect Corporation | 20.67 Million USD | 99.65% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 81.462% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 81.065% |
| IMV Inc. | 31.33 Million USD | 99.769% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 98.255% |
| MultiCell Technologies, Inc. | 126.22 USD | -57232.435% |
| ONE Bio Corp. | 70.08 Million USD | 99.897% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 92.299% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.944% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 83.238% |
| Q BioMed Inc. | 3.51 Million USD | 97.942% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.794% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 72.303% |
| Biomind Labs Inc. | 73.81 Thousand USD | 1.97% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.984% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 95.005% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.759% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 97.365% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 89.474% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 97.22% |
| GB Sciences, Inc. | 103.44 Thousand USD | 30.043% |
| Alpha Cognition Inc. | 2.45 Million USD | 97.049% |
| HST Global, Inc. | 1526.00 USD | -4642.136% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 92.675% |
| Halberd Corporation | 10.13 Thousand USD | -614.293% |
| Enzolytics Inc. | 361.7 Million USD | 99.98% |
| Agentix Corp. | 261.39 Thousand USD | 72.316% |
| Resverlogix Corp. | 8.11 Million USD | 99.108% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 96.146% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.848% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 88.687% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -217.655% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.191% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.019% |
| Zenith Capital Corp. | 7410.00 USD | -876.586% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 184.00 USD | -39228.804% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 77.513% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 72.313% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 92.202% |
| Kadimastem Ltd | 2.3 Million USD | 96.859% |
| Helix BioMedix, Inc. | 3.02 Million USD | 97.608% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.863% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.503% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -26.747% |
| LadRx Corporation | 2.3 Million USD | 96.864% |
| Cell Source, Inc. | 195.17 Thousand USD | 62.922% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 79.536% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 79.536% |
| NovAccess Global Inc. | 62.24 Thousand USD | -16.253% |
| Affymax, Inc. | 7.44 Million USD | 99.028% |
| Itoco Inc. | 1.4 Million USD | 94.831% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 24.349% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 31.731% |
| Mobile Lads Corp. | 52.00 USD | -139063.462% |
| CytoDyn Inc. | 11.13 Million USD | 99.35% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 49.385% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -304.726% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 81.227% |
| SYBLEU INC | 330.46 Thousand USD | 78.102% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 82.325% |
| International Stem Cell Corporation | 5.39 Million USD | 98.657% |
| Bioxytran, Inc. | 137.63 Thousand USD | 47.424% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.518% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.564% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 8.399% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 91.631% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.037% |
| Neutra Corp. | 2851.00 USD | -2438.232% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.777% |
| PureTech Health plc | 693.97 Million USD | 99.99% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.103% |
| IXICO plc | 15.84 Million USD | 99.543% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.126% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.93% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.978% |